US Pharma MarketingAre pharma megadeals dead? Smaller targets take priority amid hunt for blockbusters
Megadeals are largely missing in an otherwise healthy M&A environment for biopharma. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking…
Biopharma's deals landscape could hardly be better, as large companies take a multi-pronged approach to withstand an avalanche of major patent expiries.
But there’s one notable missing piece: megadeals. And it may not be coming ...
Source: Endpoints News